Arnon Rosenthal | |
|---|---|
 Rosenthal in 2018 | |
| Alma mater | Hebrew University of Jerusalem |
| Known for | Founder, President, and Chief Scientific Officer of Rinat Neuroscience Corporation, Founder and Founding CEO of Annexon Biosciences, Founder, President and CEO of Alector Therapeutics |
| Scientific career | |
| Fields | Neuroscience |
| Institutions | Hebrew University of Jerusalem, National Institute for Medical Research, Genentech, Rinat Neuroscience Corporation, Annexon Biosciences, Alector Therapeutics |
Arnon Rosenthal is an Israeli-American neuroscientist, inventor and a biotechnology entrepreneur.
Rosenthal is an inventor and developer of the pain medicine Tanezumab, the migraine medicine Fremanezumab, the Alzehimer's drug Ponezumab and the target for the basal cell carcinoma medicine Vismodegib. Rosenthal founded the biotechnology companies Rinat Neuroscience Corporation in 2001, (acquired by Pfizer in 2006[1]), Annexon,[2] which develops anti complement medicines for auto immune neuropathies and degenerative eye diseases, in 2011, and Alector, which develops innate immune (immuno-neurology) drugs for dementia and neurodegeneration, in 2013.[3][4]
References
- ↑ Pollack, Andrew (April 7, 2006). "Pfizer to Buy Rinat, a Biotechnology Drug Maker". The New York Times.
- ↑ "Founders". Annexonbio.com. Annexon Biosciences. Retrieved 21 March 2018.
- ↑ Caroll, John (October 30, 2013). "Alzheimer's experts team up with Adimab, grab $10m to launch Alector". FierceBiotech. Retrieved 21 March 2018.
- ↑ Gormley, Brian (October 24, 2017). "Alector Nabs $205 Million Via Development Deal With AbbVie". The Wall Street Journal.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.